Skip to content
value.today

HDL Therapeutics, Inc.

🇺🇸 Vero Beach, Florida, USABiotechnologyFounded 2013
Total raised
$17 M
5 rounds on record
Latest round
$1 M
Jun 2023
First round on record
May 2014
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of HDL Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$1 MNo. 5Under $2 million

HDL Therapeutics, Inc.: Raise no. 5, Jun 2023

Investors in this round

15 investors had bought by the notice of Jul 10, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $7 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series X Preferred Shares
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$277,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Brewer · Executive Officer
  • Michael Matin · Executive Officer · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer.
  • Dane Andreeff · Director
  • Gregg Sessa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Matin, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 10, 2023. Read the notice at the SEC.

equitySEC
Feb 2021$3 MNo. 4$2 to $10 million

HDL Therapeutics, Inc.: Raise no. 4, Feb 2021

Investors in this round

31 investors had bought by the notice of Mar 4, 2021: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $50 M offered; $47 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series E Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer.
  • Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer.
  • Dane Andreeff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Frontier Solutions, LLC · Richmond, VirginiaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, NC, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On fees: “The Issuer has entered into a placement agent agreement with the persons named in Item 12 under which terms such persons will receive sales commissions and other fees based on the amount of approved sales. Such amounts are unknown at this time.”

Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Mar 4, 2021. Read the notice at the SEC.

equitySEC
Sep 2019$3 MNo. 3$2 to $10 million

HDL Therapeutics, Inc.: Raise no. 3, Sep 2019

Investors in this round

34 investors had bought by the notice of Oct 3, 2019: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer.
  • Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer.
  • Dane Andreeff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Oct 3, 2019. Read the notice at the SEC.

equitySEC
Aug 2016$7 MNo. 2$2 to $10 million

HDL Therapeutics, Inc.: Raise no. 2, Aug 2016

Investors in this round

57 investors had bought by the notice of May 10, 2017: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $12 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$187,730
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer.
  • Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Morgan Stanley & Co. LLC · New York, New YorkSold in all US states
  • Frontier Solutions, LLC · Richmond, VirginiaSold in AL, AR, AZ, CA, CO, CT, DE, FL, GA, IL, IN, KY, LA, MA, MD, MN, NC, NJ, NY, OH, OR, PA, SC, TX, UT, VA, WA, WY

Remarks in the notice

  • On fees: “Commissions have been and will be paid to the persons named in Item 12 for introductions to investors.”
  • On the use of proceeds: “The gross proceeds from the offering will be used for working capital, some of which will be used to pay the salaries of related persons named in Item 3.”

Signed by Michael Matin, Chief Executive Officer of the Issuer. Source: SEC Form D and 1 amendment, newest notice filed May 10, 2017. Read the notice at the SEC.

equitySEC
May 2014$2 MNo. 1$2 to $10 million

HDL Therapeutics, Inc.: Raise no. 1, May 2014

Investors in this round

14 investors had bought by the notice of Dec 31, 2014: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Brewer · Executive Officer, Director · Dr. Brewer is the Chief Scientific Officer of the Issuer.
  • Michael Matin · Executive Officer, Director · Mr. Matin is the Chief Executive Officer and Secretary of the Issuer.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Matin, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 31, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • HDL Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2023).

    SEC Form D · Jul 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2023

That is all the official record says: HDL Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of HDL Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 57 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by HDL Therapeutics, Inc.
NameRoleNamed in
Bryan BrewerExecutive officerJul 2023
Michael MatinMr. Matin is the Chief Executive Officer and Secretary of the Issuer.Jul 2023
Dane AndreeffDirectorJul 2023
Gregg SessaDirectorJul 2023
Bryan BrewerDr. Brewer is the Chief Scientific Officer of the Issuer.Mar 2021
Michael MatinMr. Matin is the Chief Executive Officer and Secretary of the Issuer.Mar 2021